Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer

Crew, Katherine D.; Greenlee, Heather; Capodice, Jillian L.; Raptis, George; Brafman, Lois; Fuentes, Déborah; Sierra, A. de la; Hershman, Dawn L.

doi:10.1200/jco.2007.10.7573

Cited by 424 publications

(371 citation statements)

References 34 publications

Supporting

Mentioning

330

Contrasting

Unclassified

Order By: Relevance

“…The lowest incidence has been reported for exemestanetreated patients in the IES. However, other reports did not show differences in incidences of musculoskeletal symptoms between the three AIs (Crew et al 2007). These conflicting results are due to the variable definitions used in the several trials.…”

Section: Musculoskeletal Symptomsmentioning

confidence: 77%

“…Although the reported incidences of AI-induced musculoskeletal symptoms range from 5-36.0% in the large clinical trials (Howell et al 2005, Coombes et al 2007, Crew et al 2007, Gaillard & Stearns 2011, more than half of patients complain of these adverse events in the clinical setting (Presant et al 2007, Lintermans & Neven 2011. The lowest incidence has been reported for exemestanetreated patients in the IES.…”

Section: Musculoskeletal Symptomsmentioning

confidence: 96%

“…Reported clinical risk factors include prior taxane-based chemotherapy, time since menopause, low BMI, and baseline arthralgia (Crew et al 2007, Mao et al 2009). …”

Section: Musculoskeletal Symptomsmentioning

confidence: 99%

See 2 more Smart Citations

Aromatase inhibitors in the breast cancer clinic: focus on exemestane

Asten¹,

Neven²,

Lintermans³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most prevalent type of cancer in women and responsible for significant female cancer-related mortality worldwide. In the Western world, over 80% of breast cancers are hormone-receptor positive for which endocrine therapy is administered. The main anti-estrogen treatments in use consist of selective estrogen-receptor modulators, such as tamoxifen, and third-generation aromatase inhibitors (AIs), such as exemestane, letrozole, and anastrozole. In this review, the focus will lie on exemestane, its clinical use, and its side-effect profile. Exemestane is the only third-generation steroidal AI. Its efficacy as a first-line treatment in metastatic breast cancer has been demonstrated. Therefore, exemestane could be considered a valid first-line therapeutic option, but it also can be used in second-line or further situations. Exemestane is mostly used as part of sequential adjuvant treatment following tamoxifen, but in this setting it is also active in monotherapy. Furthermore, this AI has been studied in the neoadjuvant setting as presurgical treatment, and even as chemoprevention in high-risk healthy postmenopausal women. It may reverse side effects of tamoxifen, such as endometrial changes and thromboembolic disease but may also cause some inconvenient side effects itself. Additionally, there is a lack of total crossresistance between exemestane and nonsteroidal AIs as far as their anti-tumoral efficacy is concerned; moreover the two classes of AIs display a nontotal overlapping toxicity profile. Taking together, exemestane can be considered as a useful treatment option at all stages of breast cancer.

show abstract

Section: Musculoskeletal Symptomsmentioning

confidence: 77%

Section: Musculoskeletal Symptomsmentioning

confidence: 96%

See 1 more Smart Citation

Aromatase inhibitors in the breast cancer clinic: focus on exemestane

Asten¹,

Neven²,

Lintermans³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…One concern among experts was performing step exercise by patients at the risk of joint problems. Results of a study revealed that joint symptoms are very common in breast cancer patients taking aromatase inhibitors as 47% of them reported joint pain and 44% reported joint stiffness (8). Therefore, caution must be taken when prescribing step exercise, or any other kind of exercise affecting joints, for these patients.…”

Section: Discussionmentioning

confidence: 99%

Developing a Home-Based Exercise Program in Breast Cancer Patients: A Focus Group Discussion

et al. 2017

View full text Add to dashboard Cite

Background: Exercise is a major non-pharmacological intervention to improve quality of life in breast cancer patients. Given the enhanced utilization of exercise programs worldwide and lack of proper guidelines for breast cancer exercise programs in Iran, a group of different experts gathered to draw an exercise framework in these populations Methods: This is a qualitative study using a focus group discussion method. Eight participants with different expertise were gathered. We had a moderator and two assistant moderators. Results: After analyzing, two challenging themes emerged: (1) conducting different types of exercise as home-based, and (2) preparticipation assessments. We had seven subthemes for the first theme, which in turn were divided into three categories: aerobic exercises, resistance training, and exercise intensity monitoring. Also we extracted two subthemes for pre-participation assessments. Conclusions: Based on opinion of different experts who are involved in breast cancer care process, conducting different types of exercise as home-based, and pre-participation assessment should be considered.

show abstract

“…Crew and colleagues have recently published results of a prospective cohort study in which 200 women initiating AIs completed a self-administered questionnaire concerning joint pain and stiffness [15]. Nearly half of the women reported one of the two symptoms; 47% reported joint pain and 44% joint stiffness.…”

mentioning

confidence: 99%